Envestnet Asset Management
BCRX icon

Envestnet Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Envestnet Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Buy
46,137
+3,715
+9% +$33.6K ﹤0.01% 4141
2026
Q1 		$404K Sell
42,422
-11,643
-22% -$90.4K ﹤0.01% 4080
2025
Q4 		$422K Buy
54,065
+24,352
+82% +$176K ﹤0.01% 3822
2025
Q3 		$226K Buy
29,713
+19,312
+186% +$161K ﹤0.01% 4259
2025
Q2 		$93.2K Buy
10,401
+119
+1% +$1.11K ﹤0.01% 4344
2025
Q1 		$77.1K Buy
+10,282
New +$82.9K ﹤0.01% 4265
2024
Q3 		– Sell
-10,335
Closed -$63.9K – 4228
2024
Q2 		$63.9K Sell
10,335
-7,460
-42% -$41.2K ﹤0.01% 4090
2024
Q1 		$90.4K Buy
+17,795
New +$100K ﹤0.01% 4071
2018
Q3 		– Sell
-119
Closed -$1K – 1369
2018
Q2 		$1K Hold
119
– – ﹤0.01% 2786
2018
Q1 		$1K Hold
119
– – ﹤0.01% 2759
2017
Q4 		$1K Hold
119
– – ﹤0.01% 2895
2017
Q3 		$1K Hold
119
– – ﹤0.01% 2841
2017
Q2 		$1K Hold
119
– – ﹤0.01% 2982
2017
Q1 		$1K Hold
119
– – ﹤0.01% 3042
2016
Q4 		$1K Buy
+119
New +$619 ﹤0.01% 3020

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Envestnet Asset Management's BCRX Position: Q2 2026 in Review

Envestnet Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 8.8% in Q2 2026, buying an estimated $33.6K and bringing the position to 46,137 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

Envestnet Asset Management first reported a position in BCRX in Q4 2016 and has held it in 15 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Envestnet Asset Management held 46,137 shares of BioCryst Pharmaceuticals worth $461K as of Q2 2026.
  • Envestnet Asset Management bought 3,715 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $33.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4141 holding.
  • Envestnet Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2016 and has held it in 15 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.